Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $16.1600 (-3.12%) ($16.1600 - $16.1600) on Mon. Dec. 13, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.83% (three month average) | RSI | 34 | Latest Price | $16.1600(-3.12%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.2% a day on average for past five trading days. | Weekly Trend | TGTX declines -16.8% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(76%) ARKG(70%) IBB(67%) ARKK(66%) IWO(63%) | Factors Impacting TGTX price | TGTX will decline at least -2.915% in a week (0% probabilities). VIXM(-46%) VXX(-39%) UUP(-24%) UNG(-8%) USO(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.915% (StdDev 5.83%) | Hourly BBV | -1.1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $20.53 | 5 Day Moving Average | $17.03(-5.11%) | 10 Day Moving Average | $16.49(-2%) | 20 Day Moving Average | $20.53(-21.29%) | To recent high | -54.6% | To recent low | 6.5% | Market Cap | $2.047b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |